Pro-Pharmaceuticals' Davanat Enhances Antitumor Activity of Avastin/5-FU

Pro-Pharmaceuticals has announced encouraging results of preclinical experiments that include Avastin, 5-Fluorouracil (5-FU) and Davanat.

The data shows that when Davanat is co-administrated with 5-FU and the anti-vascular endothelial growth factor drug, Avastin to mice implanted with human colon tumor (COLO 205), Davanat significantly improves antitumor activities of the combination and doubles the tumor shrinkage rate.

Avastin was approved in February 2004 as a first-line treatment for metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy.